Literature DB >> 16511592

Involvement of PPAR nuclear receptors in tissue injury and wound repair.

Liliane Michalik1, Walter Wahli.   

Abstract

Tissue damage resulting from chemical, mechanical, and biological injury, or from interrupted blood flow and reperfusion, is often life threatening. The subsequent tissue response involves an intricate series of events including inflammation, oxidative stress, immune cell recruitment, and cell survival, proliferation, migration, and differentiation. In addition, fibrotic repair characterized by myofibroblast transdifferentiation and the deposition of ECM proteins is activated. Failure to initiate, maintain, or stop this repair program has dramatic consequences, such as cell death and associated tissue necrosis or carcinogenesis. In this sense, inflammation and oxidative stress, which are beneficial defense processes, can become harmful if they do not resolve in time. This repair program is largely based on rapid and specific changes in gene expression controlled by transcription factors that sense injury. PPARs are such factors and are activated by lipid mediators produced after wounding. Here we highlight advances in our understanding of PPAR action during tissue repair and discuss the potential for these nuclear receptors as therapeutic targets for tissue injury.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16511592      PMCID: PMC1386118          DOI: 10.1172/JCI27958

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  125 in total

1.  Chronic activation of PPARalpha is detrimental to cardiac recovery after ischemia.

Authors:  Nandakumar Sambandam; Dominique Morabito; Cory Wagg; Brian N Finck; Daniel P Kelly; Gary D Lopaschuk
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-09-09       Impact factor: 4.733

2.  Upregulation of type I collagen by TGF-beta in mesangial cells is blocked by PPARgamma activation.

Authors:  Feng Zheng; Alessia Fornoni; Sharon J Elliot; Youfei Guan; Matthew D Breyer; Liliane J Striker; Gary E Striker
Journal:  Am J Physiol Renal Physiol       Date:  2002-04

3.  Differential induction of PPAR-gamma by luminal glutamine and iNOS by luminal arginine in the rodent postischemic small bowel.

Authors:  N Sato; F A Moore; B C Kone; L Zou; M A Smith; M A Childs; S Moore-Olufemi; S G Schultz; R A Kozar
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2005-10-27       Impact factor: 4.052

4.  The selective cyclooxygenase-2 inhibitor SC-236 reduces liver fibrosis by mechanisms involving non-parenchymal cell apoptosis and PPARgamma activation.

Authors:  Anna Planagumà; Joan Clària; Rosa Miquel; Marta López-Parra; Esther Titos; Jaime L Masferrer; Vicente Arroyo; Joan Rodés
Journal:  FASEB J       Date:  2005-05-04       Impact factor: 5.191

5.  Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy.

Authors:  G Fragasso; P M Piatti Md; L Monti; A Palloshi; E Setola; P Puccetti; G Calori; G D Lopaschuk; A Margonato
Journal:  Am Heart J       Date:  2003-11       Impact factor: 4.749

Review 6.  Peroxisome proliferator activator receptors (PPAR), insulin resistance, and cardiomyopathy: friends or foes for the diabetic patient with heart failure?

Authors:  Lazaros A Nikolaidis; T Barry Levine
Journal:  Cardiol Rev       Date:  2004 May-Jun       Impact factor: 2.644

7.  Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway.

Authors:  Takehiro Ogata; Takashi Miyauchi; Satoshi Sakai; Masakatsu Takanashi; Yoko Irukayama-Tomobe; Iwao Yamaguchi
Journal:  J Am Coll Cardiol       Date:  2004-04-21       Impact factor: 24.094

8.  Pioglitazone, a specific ligand of the peroxisome proliferator-activated receptor gamma reduces gastric mucosal injury induced by ischaemia/ reperfusion in rat.

Authors:  P C Konturek; T Brzozowski; J Kania; V Kukharsky; K Bazela; S Kwiecien; I Harsch; S J Konturek; E G Hahn
Journal:  Scand J Gastroenterol       Date:  2003-05       Impact factor: 2.423

9.  Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the zucker Fatty rat heart.

Authors:  Robert J Sidell; Mark A Cole; Nicholas J Draper; Martine Desrois; Robin E Buckingham; Kieran Clarke
Journal:  Diabetes       Date:  2002-04       Impact factor: 9.461

10.  Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)alpha and PPARbeta mutant mice.

Authors:  L Michalik; B Desvergne; N S Tan; S Basu-Modak; P Escher; J Rieusset; J M Peters; G Kaya; F J Gonzalez; J Zakany; D Metzger; P Chambon; D Duboule; W Wahli
Journal:  J Cell Biol       Date:  2001-08-20       Impact factor: 10.539

View more
  88 in total

1.  Role of peroxisome proliferator-activated receptors alpha and gamma in gastric ulcer: An overview of experimental evidences.

Authors:  Lekha Saha
Journal:  World J Gastrointest Pharmacol Ther       Date:  2015-11-06

Review 2.  Recent advances in understanding the anti-diabetic actions of dietary flavonoids.

Authors:  Pon Velayutham Anandh Babu; Dongmin Liu; Elizabeth R Gilbert
Journal:  J Nutr Biochem       Date:  2013-09-09       Impact factor: 6.048

3.  Inhibitory effect of PPARγ agonist on the proliferation of human pterygium fibroblasts.

Authors:  Yuan Zou; Mingchang Zhang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-12-22

4.  Protective effect of 20-HETE analogues in experimental renal ischemia reperfusion injury.

Authors:  Kevin R Regner; Anna Zuk; Scott K Van Why; Brian D Shames; Robert P Ryan; John R Falck; Vijay L Manthati; Meghan E McMullen; Steven R Ledbetter; Richard J Roman
Journal:  Kidney Int       Date:  2008-12-03       Impact factor: 10.612

Review 5.  To breathe or not to breathe: the haematopoietic stem/progenitor cells dilemma.

Authors:  C Piccoli; F Agriesti; R Scrima; F Falzetti; M Di Ianni; N Capitanio
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

6.  PPARγ Agonists Attenuate Trigeminal Neuropathic Pain.

Authors:  Danielle N Lyons; Liping Zhang; Robert J Danaher; Craig S Miller; Karin N Westlund
Journal:  Clin J Pain       Date:  2017-12       Impact factor: 3.442

Review 7.  The wound healing, chronic fibrosis, and cancer progression triad.

Authors:  Brad Rybinski; Janusz Franco-Barraza; Edna Cukierman
Journal:  Physiol Genomics       Date:  2014-02-11       Impact factor: 3.107

Review 8.  Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists.

Authors:  Ramya Kapadia; Jae-Hyuk Yi; Raghu Vemuganti
Journal:  Front Biosci       Date:  2008-01-01

9.  Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma.

Authors:  Minghua Wu; Denisa S Melichian; Eric Chang; Matthew Warner-Blankenship; Asish K Ghosh; John Varga
Journal:  Am J Pathol       Date:  2009-01-15       Impact factor: 4.307

10.  Intrathecal rosiglitazone acts at peroxisome proliferator-activated receptor-gamma to rapidly inhibit neuropathic pain in rats.

Authors:  Sajay B Churi; Omar S Abdel-Aleem; Kiranjeet K Tumber; Heather Scuderi-Porter; Bradley K Taylor
Journal:  J Pain       Date:  2008-04-03       Impact factor: 5.820

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.